KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Receivables (2016 - 2025)

Neogenomics (NEO) has disclosed Receivables for 16 consecutive years, with $159.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 5.71% year-over-year to $159.2 million, compared with a TTM value of $159.2 million through Dec 2025, up 5.71%, and an annual FY2025 reading of $159.2 million, up 5.71% over the prior year.
  • Receivables was $159.2 million for Q4 2025 at Neogenomics, up from $155.3 million in the prior quarter.
  • Across five years, Receivables topped out at $159.2 million in Q4 2025 and bottomed at $105.3 million in Q1 2021.
  • Average Receivables over 5 years is $130.8 million, with a median of $128.7 million recorded in 2023.
  • Peak annual rise in Receivables hit 21.46% in 2021, while the deepest fall reached 1.29% in 2021.
  • Year by year, Receivables stood at $113.9 million in 2021, then rose by 6.83% to $121.6 million in 2022, then increased by 7.91% to $131.3 million in 2023, then rose by 14.76% to $150.6 million in 2024, then increased by 5.71% to $159.2 million in 2025.
  • Business Quant data shows Receivables for NEO at $159.2 million in Q4 2025, $155.3 million in Q3 2025, and $153.1 million in Q2 2025.